Jerome Detreille has been named senior director of New Business Development at Penn Pharma. The move is intended to drive the expansion of Penn's UK operations.
Mr. Detreille was previously at Catalent Pharma Solutions where he headed up a European Sales and Business Development team. He has 13 years of experience in selling services for conventional and highly potent drugs covering all dosage forms, from oral solid dose to sterile injectables.
Penn Pharma recently announced a $20 million investment in its South Wales, UK facility to expand its specialist high containment facilities. The new facility is due to open in January 2013.
Mr. Detreille commented, "I am fortunate to have joined such a dynamic business at a significant point in the company’s development. The expansion of our High Containment Operations will give us competitive advantage in the provision of highly potent development and contract manufacturing. I am looking forward to using my experience in negotiating large and complex deals to secure contracts for our expanded unit and hence drive growth for Penn."
